Sebelipase alfa and two investigational RNAi therapeutics, givosiran and ARO-AAT, demonstrate positive findings in treating lysosomal acid lipase deficiency and acute intermittent porphyria. Long-term tolerability and improvements in liver injury markers are observed.
Researchers used Bio-Rad's Droplet Digital PCR technology to identify potential epigenetic biomarkers for lung cancer recurrence and detect HPV cfDNA in cervical cancer patients. The studies found associations between biomarker levels and treatment outcomes, indicating the clinical utility of ddPCR technology.
The number of people receiving HCV cure is increasing with new, highly effective treatments available; simplification of treatment delivery can accelerate global scale-up. Cure leads to reductions in liver-related deaths and cancer risk, as well as improvements in comorbidities.
A single treatment of fecal microbiota transplantation produces sustained clinical and cognitive improvements in patients with liver cirrhosis and hepatic encephalopathy. The study showed significant reductions in HE episodes and hospitalizations, as well as improvements in cognitive function over 1 year.